1. Home
  2. CKPT vs KBSX Comparison

CKPT vs KBSX Comparison

Compare CKPT & KBSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CKPT
  • KBSX
  • Stock Information
  • Founded
  • CKPT 2014
  • KBSX 1976
  • Country
  • CKPT United States
  • KBSX Taiwan
  • Employees
  • CKPT N/A
  • KBSX N/A
  • Industry
  • CKPT Biotechnology: Pharmaceutical Preparations
  • KBSX Recreational Games/Products/Toys
  • Sector
  • CKPT Health Care
  • KBSX Consumer Discretionary
  • Exchange
  • CKPT Nasdaq
  • KBSX Nasdaq
  • Market Cap
  • CKPT 335.9M
  • KBSX 299.4M
  • IPO Year
  • CKPT 2017
  • KBSX N/A
  • Fundamental
  • Price
  • CKPT $4.17
  • KBSX $1.96
  • Analyst Decision
  • CKPT Buy
  • KBSX
  • Analyst Count
  • CKPT 3
  • KBSX 0
  • Target Price
  • CKPT $4.33
  • KBSX N/A
  • AVG Volume (30 Days)
  • CKPT 1.0M
  • KBSX 270.6K
  • Earning Date
  • CKPT 05-16-2025
  • KBSX 04-25-2025
  • Dividend Yield
  • CKPT N/A
  • KBSX N/A
  • EPS Growth
  • CKPT N/A
  • KBSX N/A
  • EPS
  • CKPT N/A
  • KBSX N/A
  • Revenue
  • CKPT $41,000.00
  • KBSX $33,935,076.00
  • Revenue This Year
  • CKPT $102,182.93
  • KBSX N/A
  • Revenue Next Year
  • CKPT $351.71
  • KBSX N/A
  • P/E Ratio
  • CKPT N/A
  • KBSX N/A
  • Revenue Growth
  • CKPT N/A
  • KBSX N/A
  • 52 Week Low
  • CKPT $1.47
  • KBSX $1.26
  • 52 Week High
  • CKPT $4.50
  • KBSX $15.48
  • Technical
  • Relative Strength Index (RSI)
  • CKPT 71.99
  • KBSX N/A
  • Support Level
  • CKPT $4.02
  • KBSX N/A
  • Resistance Level
  • CKPT $4.17
  • KBSX N/A
  • Average True Range (ATR)
  • CKPT 0.03
  • KBSX 0.00
  • MACD
  • CKPT -0.01
  • KBSX 0.00
  • Stochastic Oscillator
  • CKPT 93.33
  • KBSX 0.00

About CKPT Checkpoint Therapeutics Inc.

Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.

About KBSX FST Corp. Ordinary Shares

FST Corp is a renowned manufacturer and innovator in the golf industry with a growing portfolio of creative golf products, including acclaimed golf club shafts and other equipment. The Company has engaged in the research, development, manufacturing, and sales of golf club shafts. The Company currently produces and sells golf club shafts under the Company's own high-performance KBS golf club shaft brand, and serves as an original equipment manufacturer (OEM) and original design manufacturer (ODM) for other world-renowned golf equipment brands, golf equipment OEMs, and golf equipment distributors that provide consumers with customized golf club services.

Share on Social Networks: